Citigroup downgraded NuVasive from Buy to Neutral and set a new price target of $52.00 from $63.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2023 | $57.72 | Overweight → Equal Weight | Wells Fargo |
| 2/10/2023 | $63.00 → $52.00 | Buy → Neutral | Citigroup |
| 2/10/2023 | $51.00 → $52.50 | Buy → Hold | Truist |
| 1/6/2023 | Buy → Hold | Needham | |
| 10/18/2022 | $53.00 | Overweight | Barclays |
| 10/12/2022 | $45.00 | Hold | Jefferies |
| 4/13/2022 | $60.00 → $65.00 | Buy | Truist |
| 3/28/2022 | $58.00 | Overweight | Wells Fargo |
SAN DIEGO, Aug. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Scoliosis Research Society (SRS) as a double diamond sponsor and will attend the 58th Annual Meeting held September 6-9, 2023, in Seattle. "We partner with esteemed societies like SRS because of our shared dedication to clinical research, education, and thought leadership around advancing patient care, especi
NEW YORK, Aug. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 1: Goosehead Insurance Inc. (NASD: GSHD) will replace NuVasive Inc. (NASD: NUVA) in the S&P SmallCap 600. S&P MidCap 400 constituent Globus Medical Inc. (NYSE:GMED) is acquiring NuVasive in a deal expected to close soon pending final conditions.Jackson Financial Inc. (NYSE:JXN) will replace NexTier Oilfield Solutions Inc. (NYSE:NEX) in the S&P SmallCap 600. S&P SmallCap 600 constituent Patterson-UTI Energy Inc. (NASD: PTEN) is acquiring NexTier Oilfield Solutions in a deal expected to close soon pending final cond
–U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi
Wells Fargo downgraded NuVasive from Overweight to Equal Weight and set a new price target of $57.72
Citigroup downgraded NuVasive from Buy to Neutral and set a new price target of $52.00 from $63.00 previously
Truist downgraded NuVasive from Buy to Hold and set a new price target of $52.50 from $51.00 previously
4 - NUVASIVE INC (0001142596) (Issuer)
4 - NUVASIVE INC (0001142596) (Issuer)
4 - NUVASIVE INC (0001142596) (Issuer)